Cerebral haemodynamic changes induced by spinal cord stimulation in man.
P Mazzone, G Rodriguez, A Arrigo...
https://pubmed.ncbi.nlm.nih.gov/8742988/Actively Recruiting
Led by Marshall Holland · Updated on 2026-08-11
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are exploring a new non-invasive therapy for patients with aneurysmal subarachnoid hemorrhage aSAH who suffer from cerebral vasospasm CVS, a serious condition where brain arteries narrow after a bleed. This trial evaluates the use of transcutaneous vagal nerve stimulation tVNS to modulate the autonomic nervous system, aiming to reduce harmful sympathetic activity and inflammation linked to CVS. The study addresses the urgent need for improved treatments beyond current drugs and surgeries. Participants will receive tVNS therapy through a device that delivers low-intensity electrical pulses to the vagus nerve via an electrode placed on the ear. Treatment involves up to four 20-minute stimulation sessions daily during the hospital stay following standard endovascular treatment for aSAH, lasting up to 10 days. This device is already FDA-approved for other conditions like epilepsy and cluster headache. Throughout the study, participants will undergo multiple assessments including blood and cerebrospinal fluid tests to measure inflammation, transcranial Doppler imaging to monitor brain blood flow, and evaluations of clinical events such as the need for additional surgeries and hospital stay length. These measures will be taken at specified intervals from before treatment up to discharge, with monitoring lasting up to 21 days. The study aims to track the impact of tVNS on the course of cerebral vasospasm and associated complications.
CONDITIONS
The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage
M
Marshall Holland, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Marshall Holland
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | tVNS (Investigational) | Standard of Care (Context) |
|---|---|---|
| What it is | A non-invasive neuromodulation procedure using a device that stimulates the vagus nerve via electrical pulses delivered through an electrode placed near the ear. Patients receive up to 4 sessions a day, each lasting up to 20 minutes, over a 10-day period during hospitalization after endovascular repair. | Current management after endovascular treatment for cerebral vasospasm commonly includes medical therapies such as oral or intravenous calcium channel blockers (e.g., nimodipine), maintenance of adequate blood pressure and fluid status, close monitoring for delayed ischemic neurological deficit, and supportive care in a neurological intensive care setting. |
| Role in trial | Investigational neuromodulatory therapy being assessed for its effect on cerebral vasospasm and secondary complications following aneurysmal subarachnoid hemorrhage. | Established management protocol currently used as standard therapy post-endovascular treatment for the same patient population. |
| Primary use | Studied for reducing cerebral vasospasm, cerebral inflammation, and related complications after aneurysmal subarachnoid hemorrhage treated endovascularly. | Aims to prevent delayed cerebral ischemia, minimize risk of vasospasm, and support neurological recovery through established pharmacologic and supportive methods. |
| How it is given or performed | Stimulation is delivered through a small electrode placed around the ear. Patients receive up to 4 sessions per day, up to 20 minutes each, for 10 days during their inpatient post-procedure period. | Medical regimen typically includes scheduled oral nimodipine for 21 days, intravenous fluids, and monitoring in a specialized neurocritical care setting. Blood pressure may be managed with vasopressors if needed. |
| Evidence status | Safety and effectiveness are unproven in this indication. No published results are available at this time. | Medical therapies such as nimodipine and vigilant supportive care are evidence-based and widely adopted for prevention of delayed ischemia after aneurysmal subarachnoid hemorrhage. |
| Important limitations | Investigational use; effectiveness and safety are unknown in humans with cerebral vasospasm. Only a small patient population is being studied and results are not yet available. | Although current therapies such as nimodipine and supportive care reduce the risk of delayed ischemic deficits, vasospasm and secondary complications still occur and existing methods do not prevent all adverse outcomes. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 days
Participants receive transcutaneous vagal nerve stimulation (tVNS) through a device placed on the ear, delivering low-intensity electrical pulses up to four times daily for up to 20 minutes during their hospital stay following endovascular treatment.
Daily sessions during inpatient stay
Duration - Up to 21 days
Participants undergo repeated tests including blood and cerebrospinal fluid analysis, transcranial Doppler imaging, and clinical evaluations to measure inflammation, brain blood flow, and health events up to discharge.
Multiple assessments before treatment and daily until discharge
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
P Mazzone, G Rodriguez, A Arrigo...
https://pubmed.ncbi.nlm.nih.gov/8742988/Ian Phillips, Michael A Johns, Nick B Pandža...
https://pubmed.ncbi.nlm.nih.gov/40013407/I Tekdemir, A Aslan, A Elhan
https://pubmed.ncbi.nlm.nih.gov/9787391/N W Dorsch
https://pubmed.ncbi.nlm.nih.gov/7546361/Anna Maria Bombardieri, Gregory W Albers, Samuel Rodriguez...
https://pubmed.ncbi.nlm.nih.gov/36597947/Virendra Jain, Girija P Rath, Hari H Dash...
https://pubmed.ncbi.nlm.nih.gov/22096287/J Suzuki, T Iwabuchi, S Hori
https://pubmed.ncbi.nlm.nih.gov/60719/Konstantin V Slavin, Prasad Vannemreddy
https://pubmed.ncbi.nlm.nih.gov/35920945/H Hara, L Edvinsson
https://pubmed.ncbi.nlm.nih.gov/3332035/Christopher D Baggott, Beverley Aagaard-Kienitz
https://pubmed.ncbi.nlm.nih.gov/24994087/Marshall Holland
Lead Sponsor